CryoPort (CYRX) Stock Forecast & Price Target

CryoPort is positioned to benefit from an inflecting cell and gene therapy market, with 3Q26 revenue up 14% year over year to $50.2 million, Life Sciences Services up 18%, and commercial therapies up 20% as 23 commercial therapies and 788 clinical trials support growing demand. Management’s raised 2026 revenue guide of $197 million to $199 million, positive adjusted EBITDA of $1.1 million, and strong cash balance of about $393.1 million support execution, balance-sheet flexibility, and debt reduction. Its expanding global network in Santa Ana and Paris, plus higher-margin bioservices and an expected shift toward more commercial therapies, should drive operating leverage and longer-term profitability.

CryoPort is facing a fundamentally challenged outlook because its growth depends on a slower-than-expected cell and gene therapy market, where fewer approvals would directly reduce demand for its temperature-controlled logistics and services. The business also carries meaningful operational and legal risk from highly regulated cryogenic shipping, where any failed shipment, product defect, or supply chain disruption could destroy biologics, damage its reputation, and trigger litigation while pressuring margins and profitability. In addition, its global exposure, reliance on third-party carriers and software, and continued headwinds in MVE freezer demand create execution risk that could weigh on revenue growth and make the company’s competitive position less attractive.